High-Throughput Screening for mTORC1/mTORC2 Kinase Inhibitors Using a Chemiluminescence-Based ELISA Assay

被引:7
作者
Bhagwat, Shripad V. [1 ]
Kahler, Jennifer [1 ]
Yao, Yan [1 ]
Maresca, Paul
Brooks, Maureen
Crew, Andy
Boisclair, Michael
Pachter, Jonathan A. [1 ]
机构
[1] OSI Pharmaceut Inc, Dept Canc Biol, Farmingdale, NY 11735 USA
关键词
MAMMALIAN TOR; MTOR; RAPAMYCIN; PHOSPHORYLATION; TARGET;
D O I
10.1089/adt.2008.0183
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A high-throughput chemiluminescence and ELISA-based biochemical assay to identify mTORC1/mTORC2 kinase inhibitors is described. These mTOR complexes were isolated from HeLa whole cell lysate using mTOR antibodies and in-well immunoprecipitation. The integrity and purity of the mTORC1 and mTORC2 immunocomplexes were confirmed by western blotting. Full-length recombinant 4E-BP1 was used as a substrate and the catalytic activity was measured by detection of p4E-BP1 [T37/46] by a chemiluminescence method. The performance of this assay that can be used to identify dual mTORC1 and mTORC2 kinase inhibitors in a high-throughput 384-well format is described.
引用
收藏
页码:471 / 478
页数:8
相关论文
共 13 条
  • [1] RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1
    Burnett, PE
    Barrow, RK
    Cohen, NA
    Snyder, SH
    Sabatini, DM
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (04) : 1432 - 1437
  • [2] Targeting the mTOR signaling network in cancer
    Chiang, Gary G.
    Abraham, Robert T.
    [J]. TRENDS IN MOLECULAR MEDICINE, 2007, 13 (10) : 433 - 442
  • [3] Antitumor activity of rapamycin in a phase I trial for patients with recurrent PTEN-Deficient glioblastoma
    Cloughesy, Tim F.
    Yoshimoto, Koji
    Nghiemphu, Phioanh
    Brown, Kevin
    Dang, Julie
    Zhu, Shaojun
    Hsueh, Teli
    Chen, Yinan
    Wang, Wei
    Youngkin, David
    Liau, Linda
    Martin, Neil
    Becker, Don
    Bergsneider, Marvin
    Lai, Albert
    Green, Richard
    Oglesby, Tom
    Koleto, Michael
    Trent, Jeff
    Horvath, Steve
    Mischel, Paul S.
    Mellinghoff, Ingo K.
    Sawyers, Charles L.
    [J]. PLOS MEDICINE, 2008, 5 (01): : 139 - 151
  • [4] Mammalian TOR: A homeostatic ATP sensor
    Dennis, PB
    Jaeschke, A
    Saitoh, M
    Fowler, B
    Kozma, SC
    Thomas, G
    [J]. SCIENCE, 2001, 294 (5544) : 1102 - 1105
  • [5] PROTEIN SERINE THREONINE KINASES
    EDELMAN, AM
    BLUMENTHAL, DK
    KREBS, EG
    [J]. ANNUAL REVIEW OF BIOCHEMISTRY, 1987, 56 : 567 - 613
  • [6] Gingras AC, 2001, GENE DEV, V15, P2852
  • [7] Defining the role of mTOR in cancer
    Guertin, David A.
    Sabatini, David M.
    [J]. CANCER CELL, 2007, 12 (01) : 9 - 22
  • [8] Dysregulation of the TSC-mTOR pathway in human disease
    Inoki, K
    Corradetti, MN
    Guan, KL
    [J]. NATURE GENETICS, 2005, 37 (01) : 19 - 24
  • [9] Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive
    Jacinto, E
    Loewith, R
    Schmidt, A
    Lin, S
    Rüegg, MA
    Hall, A
    Hall, MN
    [J]. NATURE CELL BIOLOGY, 2004, 6 (11) : 1122 - U30
  • [10] Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
    Sarbassov, DD
    Guertin, DA
    Ali, SM
    Sabatini, DM
    [J]. SCIENCE, 2005, 307 (5712) : 1098 - 1101